Efavirenz + Emtricitabine + TDF

Form: Tablet

Strength: 600/200/300 mg

Reference Brands: Atripla(US/EU)

Category: Anti Viral

Atripla Tablets combine Efavirenz (600 mg), Emtricitabine (200 mg), and Tenofovir Disoproxil Fumarate (300 mg) in a once-daily, fixed-dose antiretroviral therapy for HIV-1 infection. Widely recommended in global HIV treatment guidelines, Atripla simplifies adherence and improves patient outcomes. On PharmaB2B platforms, global pharmaceutical buyers, NGOs, and procurement agencies can source WHO-GMP and USFDA-approved Atripla formulations from trusted manufacturers. Ideal for tender supply, HIV programs, and institutional purchases, Atripla is available for bulk export at competitive prices. Partner with verified suppliers on PharmaB2B to ensure timely, compliant delivery of high-quality antiretrovirals essential for public health programs.